Sandra Valdivielso-Moré
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sandra Valdivielso-Moré has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Laia Carla Belarte Tornero
Heart Failure Unit, Department of Cardiology, Hospital del Mar, 08003 Barcelona, Spain
5 shared publications - Núria Farré
Heart Failure Unit, Department of Cardiology, Hospital del Mar, 08003 Barcelona, Spain
5 shared publications - Sonia Ruiz-Bustillo
Department of Cardiology, Hospital del Mar , Passeig Maritim de la Barceloneta 25-29, Barcelona 08003
5 shared publications - Eduard Solé-González
Cardiology Department, Institut Clínic Cardiovascular (ICCV), Hospital Clinic de Barcelona, Universitat de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain
3 shared publications - Neus Badosa
Heart Failure Unit, Cardiology Department, Hospital del Mar, 08003 Barcelona, Spain
3 shared publications Aleksandra Mas-Stachurska
2 shared publications
Latest Publications
- 8 August 2025
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 24 (8) , 1365-1374
Effectiveness of a nurse-led telemedicine-based program for pharmacological and prognostic optimization of patients with heart failure and reduced ejection fraction: the MAR-HF-Titration study
Aims: Guidelines emphasize the importance of quadruple therapy in heart failure with reduced ejection fraction (HFrEF), and of achieving target doses quickly. The aim of the MAR-HF-Titration study was to assess the effectiveness of a nurse-led, telemedicine programme for this purpose. Methods and results: Prospective study including 210 HFrEF patients between September 2021 and December 2023. The 6-month follow-up used a telemedicine programme involving daily telemonitoring of vital signs, weight and symptoms, routine laboratory test monitoring, videoconferences and the use of algorithms for drug titration. Mean age was 70 years, 35% women. Mean left ventricle ejection fraction (LVEF) was 31%, 60% had a non-ischaemic aetiology, and 61% newly diagnosed HF. After the intervention, significant increases were achieved in the use of quadruple therapy at any dose (63 vs. 75%; P = 0.001), at ≥50% of the target doses of each drug (10 vs. 44%, P < 0.001), and at target doses of all drugs (0 vs. 19%, P < 0.001). Median titration time was 45 days for beta-blockers, 65 for MRA, and 69 for ARNI. Older age, chronic kidney disease, hypotension, and higher NTproBNP were associated with lower odds of effective titration. The LVEF increased (31–45%, P < 0.001) and the NTproBNP values were significantly reduced (1960–806 pg/mL, P < 0.001). Increases in the use of prognostic medications were also observed in a sub-analysis restricted to participants aged ≥75 years. Conclusion: Our intensive, nurse-led, telemedicine-based programme attained a fast optimization of prognostic therapies in HFrEF and resulted in significant improvements in parameters with prognostic relevance.
- 8 August 2025
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 24 (8) , 1365-1374
Effectiveness of a nurse-led telemedicine-based program for pharmacological and prognostic optimization of patients with heart failure and reduced ejection fraction: the MAR-HF-Titration study
Aims: Guidelines emphasize the importance of quadruple therapy in heart failure with reduced ejection fraction (HFrEF), and of achieving target doses quickly. The aim of the MAR-HF-Titration study was to assess the effectiveness of a nurse-led, telemedicine programme for this purpose. Methods and results: Prospective study including 210 HFrEF patients between September 2021 and December 2023. The 6-month follow-up used a telemedicine programme involving daily telemonitoring of vital signs, weight and symptoms, routine laboratory test monitoring, videoconferences and the use of algorithms for drug titration. Mean age was 70 years, 35% women. Mean left ventricle ejection fraction (LVEF) was 31%, 60% had a non-ischaemic aetiology, and 61% newly diagnosed HF. After the intervention, significant increases were achieved in the use of quadruple therapy at any dose (63 vs. 75%; P = 0.001), at ≥50% of the target doses of each drug (10 vs. 44%, P < 0.001), and at target doses of all drugs (0 vs. 19%, P < 0.001). Median titration time was 45 days for beta-blockers, 65 for MRA, and 69 for ARNI. Older age, chronic kidney disease, hypotension, and higher NTproBNP were associated with lower odds of effective titration. The LVEF increased (31–45%, P < 0.001) and the NTproBNP values were significantly reduced (1960–806 pg/mL, P < 0.001). Increases in the use of prognostic medications were also observed in a sub-analysis restricted to participants aged ≥75 years. Conclusion: Our intensive, nurse-led, telemedicine-based programme attained a fast optimization of prognostic therapies in HFrEF and resulted in significant improvements in parameters with prognostic relevance.
- Open Access
- 17 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2339
Characteristics of Patients with Heart Failure and Advanced Chronic Kidney Disease (Stages 4–5) Not Undergoing Renal Replacement Therapy (ERCA-IC Study)
Background: Despite the frequent coexistence of heart failure (HF) in patients with advanced chronic kidney disease (CKD), it has been understudied, and little is known about its prevalence and prognostic relevance. Methods: A retrospective study of 217 patients with advanced CKD (stages 4 and 5) who did not undergo renal replacement therapy (RRT). The patients were followed up for two years. The primary outcome was all-cause death or the need for RRT. Results: Forty percent of patients had a history of HF. The mean age was 78.2 ± 8.8 years and the mean eGFR was 18.4 ± 5.5 mL/min/1.73 m2. The presence of previous HF identified a subgroup of high-risk patients with a high prevalence of cardiovascular comorbidities and was significantly associated with the composite endpoint of all-cause hospitalization or need for RRT (66.7% vs. 53.1%, HR 95% CI 1.62 (1.04–2.52), p = 0.034). No differences were found in the need for RRT (27.6% vs. 32.2%, p = 0.46). Nineteen patients without HF at baseline developed HF during the follow-up and all-cause death was numerically higher (36.8 vs. 19.8%, p = 0.1). Conclusions: Patients with advanced CKD have a high prevalence of HF. The presence of previous HF identified a high-risk population with a worse prognosis that required close follow-up.
- 17 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2339
Open AccessCharacteristics of Patients with Heart Failure and Advanced Chronic Kidney Disease (Stages 4–5) Not Undergoing Renal Replacement Therapy (ERCA-IC Study)
Background: Despite the frequent coexistence of heart failure (HF) in patients with advanced chronic kidney disease (CKD), it has been understudied, and little is known about its prevalence and prognostic relevance. Methods: A retrospective study of 217 patients with advanced CKD (stages 4 and 5) who did not undergo renal replacement therapy (RRT). The patients were followed up for two years. The primary outcome was all-cause death or the need for RRT. Results: Forty percent of patients had a history of HF. The mean age was 78.2 ± 8.8 years and the mean eGFR was 18.4 ± 5.5 mL/min/1.73 m2. The presence of previous HF identified a subgroup of high-risk patients with a high prevalence of cardiovascular comorbidities and was significantly associated with the composite endpoint of all-cause hospitalization or need for RRT (66.7% vs. 53.1%, HR 95% CI 1.62 (1.04–2.52), p = 0.034). No differences were found in the need for RRT (27.6% vs. 32.2%, p = 0.46). Nineteen patients without HF at baseline developed HF during the follow-up and all-cause death was numerically higher (36.8 vs. 19.8%, p = 0.1). Conclusions: Patients with advanced CKD have a high prevalence of HF. The presence of previous HF identified a high-risk population with a worse prognosis that required close follow-up.
- 14 July 2022
- Published by Elsevier in REC: CardioClinics
- Vol. 58 (1) , 25-31
Prognostic value of apical rocking and septal flash after cardiac resynchronization
- 14 July 2022
- Published by Elsevier in REC: CardioClinics
- Vol. 58 (1) , 25-31
Prognostic value of apical rocking and septal flash after cardiac resynchronization
- Open Access
- 27 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3035
Quality of Life in Older Patients after a Heart Failure Hospitalization: Results from the SENECOR Study
Background: Information about health-related quality of life (HRQoL) in heart failure (HF) in older adults is scarce. Methods: We aimed to describe the HRQoL of the SENECOR study cohort, a single-center, randomized trial comparing the effects of multidisciplinary intervention by a geriatrician and a cardiologist (intervention group) to that of a cardiologist alone (control group) in older patients with a recent HF hospitalization. Results: HRQoL was assessed by the short version of the disease-specific Kansas Cardiomyopathy Questionnaire (KCCQ-12) in 141 patients at baseline and was impaired (KCCQ-12 < 75) in almost half of the cohort. Women comprised 50% of the population, the mean age was 82.2 years, and two-thirds of patients had preserved ejection fraction. Comorbidities were highly prevalent. Patients with impaired HRQoL had a worse NYHA functional class, a lower NT-proBNP, a lower Barthel index, and a higher Clinical Frailty Scale. One-year all-cause mortality was 22.7%, significantly lower in the group with good-to-excellent HRQoL (14.5% vs. 30.6%; hazard ratio 0.28; 95% confidence interval 0.10–0.78; p = 0.014). In the group with better HRQoL, all-cause hospitalization was lower, and there was a trend towards lower HF hospitalization. Conclusions: The KCCQ-12 questionnaire can provide inexpensive prognostic information even in older patients with HF. (Funded by grant Primitivo de la Vega, Fundación MAPFRE. ClinicalTrials number, NCT03555318).
- 27 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3035
Open AccessQuality of Life in Older Patients after a Heart Failure Hospitalization: Results from the SENECOR Study
Background: Information about health-related quality of life (HRQoL) in heart failure (HF) in older adults is scarce. Methods: We aimed to describe the HRQoL of the SENECOR study cohort, a single-center, randomized trial comparing the effects of multidisciplinary intervention by a geriatrician and a cardiologist (intervention group) to that of a cardiologist alone (control group) in older patients with a recent HF hospitalization. Results: HRQoL was assessed by the short version of the disease-specific Kansas Cardiomyopathy Questionnaire (KCCQ-12) in 141 patients at baseline and was impaired (KCCQ-12 < 75) in almost half of the cohort. Women comprised 50% of the population, the mean age was 82.2 years, and two-thirds of patients had preserved ejection fraction. Comorbidities were highly prevalent. Patients with impaired HRQoL had a worse NYHA functional class, a lower NT-proBNP, a lower Barthel index, and a higher Clinical Frailty Scale. One-year all-cause mortality was 22.7%, significantly lower in the group with good-to-excellent HRQoL (14.5% vs. 30.6%; hazard ratio 0.28; 95% confidence interval 0.10–0.78; p = 0.014). In the group with better HRQoL, all-cause hospitalization was lower, and there was a trend towards lower HF hospitalization. Conclusions: The KCCQ-12 questionnaire can provide inexpensive prognostic information even in older patients with HF. (Funded by grant Primitivo de la Vega, Fundación MAPFRE. ClinicalTrials number, NCT03555318).
- Open Access
- 30 March 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (7) , 1932
Randomized Controlled Trial Comparing a Multidisciplinary Intervention by a Geriatrician and a Cardiologist to Usual Care after a Heart Failure Hospitalization in Older Patients: The SENECOR Study
Background: The prognosis of older patients after a heart failure (HF) hospitalization is poor. Methods: In this randomized trial, we consecutively assigned 150 patients 75 years old or older with a recent heart failure hospitalization to follow-up by a cardiologist (control) or follow-up by a cardiologist and a geriatrician (intervention). The primary outcome was all-cause hospitalization at a one-year follow-up. Results: All-cause hospitalization occurred in 47 of 75 patients (62.7%) in the intervention group and in 58 of 75 patients (77.3%) in the control group (hazard ratio, 0.67; 95% confidence interval, 0.46 to 0.99; p = 0.046). The number of patients with at least one HF hospitalization was similar in both groups (34.7% in the intervention group vs. 40% in the control group, p = 0.5). There were a total of 236 hospitalizations during the study period. The main reasons for hospitalization were heart failure (38.1%) and infection (14.8%). Mortality was 24.7%. Heart failure was the leading cause of mortality (54.1% of all deaths), without differences between groups. Conclusions: A follow-up by a cardiologist and geriatrician in older patients after an HF hospitalization was superior to a cardiologist’s follow-up in reducing all-cause hospitalization in older patients. (Funded by Beca Primitivo de la Vega, Fundación MAPFRE. ClinicalTrials.gov number, NCT03555318).
- 30 March 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (7) , 1932
Open AccessRandomized Controlled Trial Comparing a Multidisciplinary Intervention by a Geriatrician and a Cardiologist to Usual Care after a Heart Failure Hospitalization in Older Patients: The SENECOR Study
Background: The prognosis of older patients after a heart failure (HF) hospitalization is poor. Methods: In this randomized trial, we consecutively assigned 150 patients 75 years old or older with a recent heart failure hospitalization to follow-up by a cardiologist (control) or follow-up by a cardiologist and a geriatrician (intervention). The primary outcome was all-cause hospitalization at a one-year follow-up. Results: All-cause hospitalization occurred in 47 of 75 patients (62.7%) in the intervention group and in 58 of 75 patients (77.3%) in the control group (hazard ratio, 0.67; 95% confidence interval, 0.46 to 0.99; p = 0.046). The number of patients with at least one HF hospitalization was similar in both groups (34.7% in the intervention group vs. 40% in the control group, p = 0.5). There were a total of 236 hospitalizations during the study period. The main reasons for hospitalization were heart failure (38.1%) and infection (14.8%). Mortality was 24.7%. Heart failure was the leading cause of mortality (54.1% of all deaths), without differences between groups. Conclusions: A follow-up by a cardiologist and geriatrician in older patients after an HF hospitalization was superior to a cardiologist’s follow-up in reducing all-cause hospitalization in older patients. (Funded by Beca Primitivo de la Vega, Fundación MAPFRE. ClinicalTrials.gov number, NCT03555318).
- 16 March 2022
- Published by Elsevier in REC: CardioClinics
- Vol. 57 (2) , 69-71
Risk stratification in heart failure. A new score for risk assessment in ambulatory patients with chronic heart failure
- 16 March 2022
- Published by Elsevier in REC: CardioClinics
- Vol. 57 (2) , 69-71
Risk stratification in heart failure. A new score for risk assessment in ambulatory patients with chronic heart failure
- 1 April 2021
- Published by Elsevier in REC: CardioClinics
- Vol. 56 (2) , 108-117
Influence of cardiovascular disease and cardiovascular risk factors in COVID-19 patients. Data from a large prospective Spanish cohort
- 1 April 2021
- Published by Elsevier in REC: CardioClinics
- Vol. 56 (2) , 108-117
Influence of cardiovascular disease and cardiovascular risk factors in COVID-19 patients. Data from a large prospective Spanish cohort
- Open Access
- 17 January 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (2) , 323
Prognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection
Background: The prevalence and prognostic value of chronic heart failure (CHF) in the setting of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has seldom been studied. The aim of this study was to analyze the prevalence and prognosis of CHF in this setting. Methods: This single-center study included 829 consecutive patients with SARS-CoV-2 infection from February to April 2020. Patients with a previous history of CHF were matched 1:2 for age and sex. We analyze the prognostic value of pre-existing CHF. Prognostic implications of N terminal pro brain natriuretic peptide (NT-proBNP) levels on admission in the CHF cohort were explored. Results: A total of 129 patients (43 CHF and 86 non-CHF) where finally included. All-cause mortality was higher in CHF patients compared to non-CHF patients (51.2% vs. 29.1%, p = 0.014). CHF was independently associated with 30-day mortality (hazard ratio (HR) 2.3, confidence interval (CI) 95%: 1.26–2.4). Patients with CHF and high-sensitivity troponin T < 14 ng/L showed excellent prognosis. An NT-proBNP level > 2598 pg/mL on admission was associated with higher 30-day mortality in patients with CHF. Conclusions: All-cause mortality in CHF patients hospitalized due to SARS-CoV-2 infection was 51.2%. CHF was independently associated with all-cause mortality (HR 2.3, CI 95% 1.26–4.2). NT-proBNP levels could be used for stratification risk purposes to guide medical decisions if larger studies confirm this finding.
- 17 January 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (2) , 323
Open AccessPrognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection
Background: The prevalence and prognostic value of chronic heart failure (CHF) in the setting of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has seldom been studied. The aim of this study was to analyze the prevalence and prognosis of CHF in this setting. Methods: This single-center study included 829 consecutive patients with SARS-CoV-2 infection from February to April 2020. Patients with a previous history of CHF were matched 1:2 for age and sex. We analyze the prognostic value of pre-existing CHF. Prognostic implications of N terminal pro brain natriuretic peptide (NT-proBNP) levels on admission in the CHF cohort were explored. Results: A total of 129 patients (43 CHF and 86 non-CHF) where finally included. All-cause mortality was higher in CHF patients compared to non-CHF patients (51.2% vs. 29.1%, p = 0.014). CHF was independently associated with 30-day mortality (hazard ratio (HR) 2.3, confidence interval (CI) 95%: 1.26–2.4). Patients with CHF and high-sensitivity troponin T < 14 ng/L showed excellent prognosis. An NT-proBNP level > 2598 pg/mL on admission was associated with higher 30-day mortality in patients with CHF. Conclusions: All-cause mortality in CHF patients hospitalized due to SARS-CoV-2 infection was 51.2%. CHF was independently associated with all-cause mortality (HR 2.3, CI 95% 1.26–4.2). NT-proBNP levels could be used for stratification risk purposes to guide medical decisions if larger studies confirm this finding.
- 1 October 2020
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 26 (10) , S163
Transthyretin Cardiac Amyloidosis: Patient Characteristics in Our Region
- 1 October 2020
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 26 (10) , S163
Transthyretin Cardiac Amyloidosis: Patient Characteristics in Our Region
- Open Access
- 31 August 2019
- Published by Cardiofront, LLC in Journal of Atrial Fibrillation
- Vol. 12 (2) , 2225
Contemporary Yield of 24-hour Holter Monitoring: Role of Inter-Atrial Block Recognition
Background The diagnostic yield of 24-hour ECG Holter monitoring (24H) is currently overcome by alternative ECG monitoring techniquesand it needs to be optimized. The recognition of inter-atrial block (IAB) has emerged as a reliable indicator of patients at risk of atrial fibrillation relapses, and its role enhancing the yield of 24H is yet to be determined. We hypothesized that a presumably low yield of 24H may be ameliorated by means of incorporating the assessment for IAB. Methods We retrospectively analyzed 1017 consecutive 24H registers performed in a Multidisciplinary Integrated Health Care Institution, in which a restrictive definition of diagnostic 24H findings was used. A univariate and multivariate regression analysis served to determine the variables associated with a higher 24H’s yield, including the requesting medical specialty, type of indication and a number of clinical, echocardiographic and ECG variables, including IAB. Results The mean age of our population was 62 ± 17 years (55% males). The majority of 24H were indicated from the Cardiology department (48%). The overall yield was 12.8%, higher for the assessment of the integrity of the electrical conduction system (26.1%) and poorer for the assessment of syncope (3.2%) and cryptogenic stroke (4.6%). The variables associated with higher diagnostic performance were indication from Cardiology (p < 0.001), IAB (p = 0.004), structural heart disease (p = 0.008) and chronic renal failure (p = 0.009). Patients ≤ 50 years old only retrieved a 7% yield. In the multivariate analysis, indication from Cardiology and IAB remained significant predictors of higher 24H’s yield. In a secondary analysis including echocardiographic data, only identification of IAB remained statistically significant. Conclusions The recognition of IAB and the type of indication are major determinants of a higher 24H’s diagnostic yield and may help to optimize the selection of candidates.
- 31 August 2019
- Published by Cardiofront, LLC in Journal of Atrial Fibrillation
- Vol. 12 (2) , 2225
Open AccessContemporary Yield of 24-hour Holter Monitoring: Role of Inter-Atrial Block Recognition
Background The diagnostic yield of 24-hour ECG Holter monitoring (24H) is currently overcome by alternative ECG monitoring techniquesand it needs to be optimized. The recognition of inter-atrial block (IAB) has emerged as a reliable indicator of patients at risk of atrial fibrillation relapses, and its role enhancing the yield of 24H is yet to be determined. We hypothesized that a presumably low yield of 24H may be ameliorated by means of incorporating the assessment for IAB. Methods We retrospectively analyzed 1017 consecutive 24H registers performed in a Multidisciplinary Integrated Health Care Institution, in which a restrictive definition of diagnostic 24H findings was used. A univariate and multivariate regression analysis served to determine the variables associated with a higher 24H’s yield, including the requesting medical specialty, type of indication and a number of clinical, echocardiographic and ECG variables, including IAB. Results The mean age of our population was 62 ± 17 years (55% males). The majority of 24H were indicated from the Cardiology department (48%). The overall yield was 12.8%, higher for the assessment of the integrity of the electrical conduction system (26.1%) and poorer for the assessment of syncope (3.2%) and cryptogenic stroke (4.6%). The variables associated with higher diagnostic performance were indication from Cardiology (p < 0.001), IAB (p = 0.004), structural heart disease (p = 0.008) and chronic renal failure (p = 0.009). Patients ≤ 50 years old only retrieved a 7% yield. In the multivariate analysis, indication from Cardiology and IAB remained significant predictors of higher 24H’s yield. In a secondary analysis including echocardiographic data, only identification of IAB remained statistically significant. Conclusions The recognition of IAB and the type of indication are major determinants of a higher 24H’s diagnostic yield and may help to optimize the selection of candidates.